Thyrotropin alfa - Biologic Drug Details

Summary for thyrotropin alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for thyrotropin alfa

Recent Clinical Trials for thyrotropin alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AHS Cancer Control Alberta	PHASE2
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	PHASE4
Sun Yat-sen University	Phase 2

See all thyrotropin alfa clinical trials

Pharmacology for thyrotropin alfa

Established Pharmacologic Class	Thyroid Stimulating Hormone
Chemical Structure	Thyrotropin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for thyrotropin alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for thyrotropin alfa Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for thyrotropin alfa Derived from Patent Text Search

No patents found based on company disclosures

Thyrotropin alfa Market Analysis and Financial Projection

Last updated: February 16, 2026

What is the current state of the market for thyrotropin alfa?

Thyrotropin alfa, marketed as Thyrogen, is a recombinant form of human thyroid-stimulating hormone. Its primary use is to facilitate radioactive iodine scanning and therapy in thyroid cancer patients. Since FDA approval in 1998 and EMA approval in 1999, the drug's market presence has been stable, with specialized application in thyroid oncology.

Market estimates for thyrotropin alfa's global sales projected approximately $150 million in 2022, with a compound annual growth rate (CAGR) of 4% over the past five years. Growth is primarily driven by increased thyroid cancer diagnoses and prolonged use of adjuvant therapies. Certain markets, notably the U.S., account for approximately 60% of sales, reflecting higher clinical adoption and reimbursement coverage.

What are the key drivers influencing thyrotropin alfa market expansion?

Rising Incidence of Thyroid Cancer

Thyroid cancers have shown an increasing trend, with global annual diagnoses rising at approximately 4% per year over the last decade. The American Cancer Society reported 52,000 new cases in the U.S. in 2021. Advancements in diagnostic imaging and increased awareness lead to earlier detection, enlarging the patient base eligible for thyrotropin alfa.

Advancements in Diagnostic Imaging and Treatment Protocols

Enhanced imaging techniques, such as whole-body scans post-radioactive iodine therapy, require TSH stimulation. Thyrotropin alfa replaces the traditional method of hypothyroidism induction via thyroid hormone withdrawal, providing a more patient-friendly alternative. This encourages clinicians to adopt thyrotropin alfa, especially in outpatient settings.

Regulatory and Reimbursement Environment

Reimbursement acceptance for thyrotropin alfa is high in developed markets, supporting stable sales. However, approval and coverage variability exist in emerging markets, limiting growth potential. Recent health policy trends favor targeted biologic therapies with clear clinical benefits.

Competition and Patent Landscape

No direct biosimilars of thyrotropin alfa have received regulatory approval as of 2022. Patent protections, granted in 2001 and extended until 2025, prevent biosimilar entry. This exclusivity sustains pricing power but constrains long-term market expansion.

What are the financial trends and forecasts for thyrotropin alfa?

Revenue Trends

Sales have modestly increased from approximately $125 million in 2018 to $150 million in 2022. The steady growth reflects increased diagnosis rates but constrained by the drug’s specialized use and limited geographic reach.

Cost Structure and Pricing

The average wholesale price (AWP) in the U.S. for a single vial hovers around $600–$700 (as of 2022). The high per-dose cost is justified by the production complexity of recombinant proteins and regulatory compliance expenses. Cost containment pressures in healthcare may influence pricing strategies moving forward.

Investment and R&D Pipeline

Currently, no significant R&D pipelines target biosimilar versions due to patent expiration upcoming in 2025. However, companies are exploring adjacent therapies in thyroid cancer management, which could indirectly impact thyrotropin alfa's market share.

Potential Market Expansion

Future growth relies on increased adoption in emerging markets and potential label expansions, such as use in other thyroid-related diagnostic procedures. Clinical trials are investigating its utility in differentiated thyroid carcinoma management beyond current indications.

What are the regulatory and patent considerations affecting future market trajectory?

Patent Expiry and Biosimilar Entry

Patent protections maintained until 2025 prevent biosimilar competition. Once expired, biosimilar products are anticipated to enter the market, potentially reducing prices and pressuring existing revenue streams.

Regulatory Pathways

Biosimilar approval will depend on demonstrating similarity in safety, efficacy, and immunogenicity. Regulatory agencies such as FDA and EMA have clear pathways, with the potential for rapid approval if biosimilars meet all requirements.

Market Adoption and Reimbursement Policies

Reimbursement policies significantly influence biosimilar uptake. Countries that actively promote biosimilar substitution could see rapid market penetration, reducing health care costs.

How do competitive and external factors influence classification and outlook?

Competitive Landscape

No biosimilars are approved yet. Current market dominance by the originator limits market share erosion. However, entry of biosimilars post-patent expiration could significantly alter the landscape.

External Factors

Healthcare policies favoring cost reduction, ongoing clinical research, and global thyroid cancer trends impact market growth. Economic recessions or healthcare budget constraints could slow adoption or reimbursement levels.

Key Takeaways

• The thyrotropin alfa market is stable but limited to specialized indications, with sales around $150 million globally.
• Growth drivers include rising thyroid cancer incidence, improved diagnostic protocols, and established reimbursement environments.
• Patent protections until 2025 delay biosimilar competition; post-expiration, biosimilars are expected to reduce prices and expand access.
• No current biosimilars are approved; future market dynamics depend heavily on regulatory approvals and healthcare policies.
• Expansion prospects hinge on increased use in emerging markets and potential new indications, alongside competitive biosimilar entry.

FAQs

What factors could accelerate breastplate growth for thyrotropin alfa?
Increased thyroid cancer diagnosis rates, regulatory approvals for new indications, and wider biosimilar adoption post-2025.

How does biosimilar competition impact the existing market?
Entry of biosimilars could lower prices by 20-30%, erode market share, and prompt shifts in prescribing practices.

Are there ongoing clinical trials aiming to expand thyrotropin alfa applications?
Yes, recent trials explore its use in differentiated thyroid carcinoma management and novel diagnostic approaches, which could broaden its indications.

What are the primary challenges facing thyrotropin alfa commercialization?
Limited geographic coverage, high manufacturing costs, and potential biosimilar competition post-2025.

How might healthcare policy changes influence the revenue trajectory?
Reimbursement shifts toward cost-effective therapies and policies encouraging biosimilar use could pressure pricing and sales volume.

---

Sources

[1] EvaluatePharma, 2022. "Thyrotropin alfa Market Analysis."
[2] American Cancer Society, 2021. "Thyroid Cancer Facts & Figures."
[3] U.S. Food and Drug Administration, 2022. "Biosimilar Product Development and Approval."
[4] European Medicines Agency, 2022. "Guidelines on Biosimilar Medicinal Products."